On 15 October 2024, Johnson & Johnson (J&J) reported its results for Q3 2024, which saw sales growth of 5.2% to $22.5B. J&J’s significant regulatory announcements this quarter include applications for expanded US and EU indications of Darzalex® (daratumumab) and Darzalex Faspro® (daratumumab and hyaluronidase-fihj) based quadruplet regimens for multiple myeloma (October 2024) and FDA approval for Rybrevant® (amivantamab-vmjw) in combination with standard of care for the treatment non-small cell lung cancer (September 2024).
On the same day, Genmab announced that net sales of Darzalex® (daratumumab) in the third quarter of 2024, as reported by J&J, totalled USD 3,016 million. US sales accounted for more than half of this total, reaching USD 1,684 million. Genmab receives royalties on the worldwide net sales of Darzalex®, both the intravenous and SC products, under its exclusive worldwide license to Janssen to develop, manufacture and commercialise daratumumab.